查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009110

偏頭痛治療市場規模、佔有率、趨勢和預測：按治療類型、藥物類型、給藥途徑、分銷管道和地區分類，2026-2034 年

Migraine Drugs Market Size, Share, Trends and Forecast by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球偏頭痛治療市場規模為46億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以3.90%的複合年成長率成長，到2034年達到65億美元。目前，北美市場主導地位，預計2025年將佔30%的市場。該地區受益於許多因素，例如完善的醫療保健基礎設施、較高的診斷率、涵蓋先進偏頭痛治療的廣泛保險覆蓋，以及對新型CGRP（抑鈣素基因相關胜肽）治療方法的積極應用，所有這些因素都為其在偏頭痛治療市場佔據領先地位做出了貢獻。

偏頭痛的日益普及（影響全球超過十億人）是推動全球偏頭痛治療市場發展的主要動力。人們越來越認知到偏頭痛是一種神經系統疾病，快速診斷和治療的重要性也日益凸顯，這促使人們對有效治療方法的需求不斷成長。此外，諸如抗偏頭痛藥物和抑鈣素基因相關胜肽（CGRP）抑制劑等新型藥物的出現，憑藉其特異性的作用機制、優異的耐受性和療效，正在改變偏頭痛的治療模式。不斷擴大的治療選擇（包括急性治療和預防性治療）以及個人化醫療方法的日益普及，進一步推動了偏頭痛治療市場的成長。此外，製藥公司不斷增加的研發投入也加速了新療法的上市。

由於多種原因，美國是偏頭痛藥物的重要市場。久坐的生活方式、工作年齡帶來的壓力以及螢幕使用時間的增加，導致偏頭痛在美國十分普遍。完善的醫療保健體系、優惠的支付政策以及處方箋偏頭痛藥物的廣泛醫保覆蓋，推動了尖端治療方法的應用。此外，許多大型製藥企業對臨床試驗和藥物研發的投入，也促進了新型偏頭痛藥物的上市。遠端醫療平台和數位健康工具在偏頭痛管理中的日益普及，進一步提高了患者獲得適當治療的機會，也為偏頭痛藥物市場的發展前景提供了支撐。此外，旨在消除偏頭痛污名的宣傳活動也不斷擴大，這有助於提高全國範圍內的偏頭痛診斷率和治療率。

偏頭痛治療市場的發展趨勢：

廣泛採用CGRP標靶治療方法

偏頭痛治療市場的主要驅動力是針對抑鈣素基因相關胜肽 (CGRP) 的治療方法的激增。 CGRP 單株抗體和小分子拮抗劑（也稱為「吉泮」）透過直接作用於偏頭痛發作的潛在病理生理機制，正在為偏頭痛治療帶來模式轉移。與傳統藥物相比，這些技術在療效和耐受性方面均提供了更優的急性期和預防性治療選擇。越來越多的臨床數據證實了 CGRP 標靶治療方法的長期益處，這促使患者和臨床醫生對其接受度不斷提高。例如，2025 年 8 月，美國食品藥物管理局(FDA) 批准了首個抗 CGRP 療法 fremanezumab，用於預防 6 至 17 歲、體重 45 公斤及核准的兒童患者的陣發性偏頭痛。此外，包括口服製劑和聯合治療在內的新一代 CGRP標靶藥物的研發管線不斷擴大，為各種患者群體提供了更廣泛的治療選擇，從而增強了偏頭痛治療市場的前景。

聯合治療的需求日益成長

偏頭痛治療市場最顯著的趨勢之一是對聯合治療的需求日益成長。聯合治療將多種作用機制整合到單一製劑中，因其能夠提供全面、快速且持久的偏頭痛緩解而越來越受歡迎。這些治療方法透過作用於偏頭痛病理生理學中的多個通路，克服了單一療法的不足，從而提高了無痛率，減少了症狀復發，並克服了單一療法的局限性。例如，2025年1月，美國食品藥物管理局（FDA）核准了由Axsome Therapeutics公司開發的新型口服複方製劑Symbravo，用於治療成人急性偏頭痛。此複方製劑由美洛昔康和Rizatriptan組成。臨床試驗表明，Symbravo單次給藥後兩小時內即可緩解疼痛，藥效永續長達48小時。隨著製藥公司加強對創新聯合治療研發的投入，對多重機制藥物設計的日益重視正在推動偏頭痛治療市場的發展趨勢。

數位醫療解決方案的整合正在穩步推進。

數位健康技術在偏頭痛治療領域的日益普及，正在重振偏頭痛藥物市場。人工智慧驅動的偏頭痛監測應用程式、遠端醫療平台和數位療法正在革新患者接受治療、監測症狀和遵循治療方案的方式。在神經科和頭痛專家資源有限的低度開發地區，這些技術進步正在幫助彌合患者與醫療服務提供者之間的鴻溝。由於線上諮詢的便利性，更多患者能夠獲得快速診斷和針對偏頭痛急性期和預防性治療的合適處方。此外，穿戴式科技和行動醫療應用程式的廣泛應用，也推動了偏頭痛治療精準化的趨勢，使醫療專業人員能夠根據患者的個別數據客製化治療方案。隨著製藥公司和數位健康公司之間合作的不斷深化以及一體化治療生態系統的構建，全球患者可選擇的偏頭痛管理方案將進一步擴展。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球偏頭痛治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療類型分類

  • 癲癇發作期間的治療
  • 預防性治療

第7章 市場區隔：依藥物類型分類

  • 曲坦類藥物
  • 麥角生物鹼
  • NSAIDs
  • 乙醯膽鹼抑制劑/神經毒素
  • 以地坦為基礎的藥物
  • CGRP單株抗體
  • 其他

第8章 市場區隔：依給藥途徑

  • 口服
  • 注射藥物
  • 其他

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Allergan Plc（Abbvie Inc.）
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
Product Code: SR112026A2543

The global migraine drugs market size was valued at USD 4.60 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.50 Billion by 2034, exhibiting a CAGR of 3.90% from 2026-2034. North America currently dominates the market, holding a market share of 30% in 2025. The region benefits from a well-established healthcare infrastructure, high diagnosis rates, widespread insurance coverage for advanced migraine therapies, and strong adoption of novel CGRP-based treatments, all supporting the migraine drugs market share.

The growing incidence of migraine disorders, which impact more than one billion people worldwide, is the main factor propelling the global market for migraine medications. The need for efficient therapeutic treatments is being driven by rising recognition of migraine as a neurological disorder and the importance of prompt diagnosis and treatment. Furthermore, the emergence of new medication classes, such as gepants and calcitonin gene-related peptide (CGRP) inhibitors, is changing the therapeutic environment by providing focused modes of action with better tolerance and effectiveness profiles. The expanding availability of both acute and preventive treatment options, along with the rising adoption of personalized medicine approaches, is further augmenting the migraine drugs market growth. Furthermore, the release of novel treatments is being accelerated by pharmaceutical corporations' increasing expenditure in research and development.

For a variety of reasons, the US has become a significant market for migraine medications. Due to sedentary lifestyles, stressors associated with the working age population, and increased screen time, migraine problems are highly prevalent in the nation. The adoption of cutting-edge treatment alternatives is being aided by the well-established healthcare system, advantageous payment regulations, and extensive insurance coverage for prescription migraine medications. Additionally, the introduction of novel migraine remedies is being aided by the large number of top pharmaceutical companies who are investing in clinical studies and drug research. The increasing utilization of telemedicine platforms and digital health tools for migraine management is further enhancing patient access to appropriate care, supporting the migraine drugs market outlook. Improved diagnosis and treatment rates nationwide are also a result of the expanding advocacy and awareness activities aimed at lowering the stigma associated with migraines.

Migraine Drugs Market Trends:

Growing Adoption of CGRP-Targeted Therapies

The market for migraine medications is being driven mostly by the growing use of treatments that target calcitonin gene-related peptide (CGRP). By directly addressing the underlying pathophysiology of migraine attacks, CGRP monoclonal antibodies and small-molecule antagonists, also referred to as gepants, represent a paradigm shift in migraine treatment. When compared to traditional pharmaceuticals, these technologies offer both acute and preventive therapeutic alternatives with improved effectiveness and tolerability profiles. The increasing amount of clinical data demonstrating the long-term advantages of CGRP-based therapies is promoting broader patient and clinician acceptance. For instance, in August 2025, the United States Food and Drug Administration approved fremanezumab as the first anti-CGRP therapy for the preventive treatment of episodic migraine in pediatric patients aged 6 to 17 who weigh at least 45 kg. Furthermore, the expanding pipeline of next-generation CGRP-targeted agents, including oral formulations and combination therapies, is broadening the therapeutic options available for diverse patient populations, thereby strengthening the migraine drugs market forecast.

Rising Demand for Combination Drug Therapies

One of the most noticeable trends in the market for migraine medications is the growing need for combination medication treatments. Combination therapies, which incorporate several modes of action into one formulation, are becoming more popular because of their capacity to offer complete, quick, and long-lasting migraine relief. These treatments increase pain freedom rates and decrease symptom recurrence by focusing on several pathways implicated in migraine pathophysiology, which overcomes the drawbacks of monotherapy techniques. For instance, in January 2025, the United States Food and Drug Administration approved Symbravo, a novel oral combination of meloxicam and rizatriptan developed by Axsome Therapeutics, for the acute treatment of migraine in adults. Clinical trials demonstrated that Symbravo provided pain freedom within two hours with sustained efficacy for up to 48 hours after a single dose. The growing emphasis on multi-mechanistic drug design is encouraging pharmaceutical companies to invest in the development of innovative combination therapies, enhancing migraine drugs market trends.

Increasing Integration of Digital Health Solutions

The market for migraine medications is being stimulated by the growing incorporation of digital health technologies into migraine treatment. Artificial intelligence-powered migraine monitoring apps, telemedicine platforms, and digital therapies are revolutionizing how patients get care, monitor their symptoms, and follow treatment plans. In underprivileged areas with little access to neurologists and headache experts, these technological developments are helping to close the gap between patients and healthcare professionals. More patients are being able to obtain prompt diagnoses and suitable prescriptions for both acute and preventive migraine treatments thanks to the increasing convenience of virtual consultations. Furthermore, the trend toward precision medicine in migraine care is being supported by the increasing use of wearable technology and mobile health apps for real-time migraine tracking, which allow medical professionals to customize treatment regimens based on unique patient data. The range of migraine management options available to patients globally is being further expanded by the growing cooperation between pharmaceutical corporations and digital health firms to create integrated treatment ecosystems.

Migraine Drugs Industry Segmentation:

Analysis by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment

Abortive treatment holds 59% of the market share. Abortive treatment, also referred to as acute treatment, encompasses medications administered during a migraine attack to alleviate symptoms and restore normal functioning. These treatments function by focusing on the vascular and neurological processes that cause migraine discomfort, such as the suppression of the CGRP pathway, the activation of serotonin receptors, and the decrease of neuroinflammation. The high frequency of patients' migraine attacks, which require prompt symptom alleviation, is the reason for the abortive treatment segment's dominance. Additionally, patients and clinicians have a variety of alternatives for efficiently managing acute episodes due to the availability of varied medication classes, such as NSAIDs and triptans. For instance, according to the World Health Organization, headache disorders are among the three most common neurological conditions globally across most age groups between five and 80 years of age. Furthermore, the introduction of novel rapid-acting therapies with improved bioavailability and sustained efficacy is expanding the range of abortive treatment solutions available to migraine sufferers.

Analysis by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others

Triptans lead the market with a share of 30%. Triptans are a class of selective serotonin 5-HT1B/1D receptor agonists that provide effective relief from moderate to severe migraine attacks by constricting dilated cranial blood vessels and inhibiting neuropeptide release. Their well-established pharmacological action, decades of clinical use, and proven efficacy across varying migraine severity levels have ensured consistent physician preference and patient reliance. The availability of multiple triptan formulations, including oral tablets, nasal sprays, and injectable preparations, provides treatment flexibility and enhances patient compliance across diverse patient populations. The widespread acceptance of sumatriptan and other triptan variants as first-line acute migraine therapies has consolidated their role as a cornerstone of migraine treatment protocols globally. Furthermore, regulatory approvals across multiple geographies and formulary inclusion in both public and private insurance plans have expanded access to triptan-based treatments. The continued refinement of triptan formulations with enhanced absorption profiles and improved bioavailability is further reinforcing their position within the migraine drugs market.

Analysis by Route of Administration:

  • Oral
  • Injectable
  • Others

Oral dominates the market, with a share of 67%. Oral route of administration represents the most widely utilized delivery method for migraine drugs owing to its convenience, ease of use, and patient acceptability. Oral formulations, including tablets, capsules, and orally disintegrating tablets, allow patients to self-administer medication without the need for healthcare professional assistance, supporting timely treatment initiation during migraine attacks. The broad availability of oral formulations across multiple drug classes, including triptans, NSAIDs, gepants, and combination therapies, ensures comprehensive coverage for both acute and preventive migraine management. The growing focus on developing advanced oral delivery technologies that enable faster drug absorption and prolonged plasma half-life is further enhancing the therapeutic performance of oral migraine medications. Moreover, the ongoing development of rapid-absorption technologies utilized in recently approved combination therapies is enhancing the pharmacokinetic profiles of oral migraine drugs, enabling faster onset of action while maintaining sustained therapeutic efficacy. The preference among patients for non-invasive treatment options continues to reinforce oral administration as the dominant delivery route in the market.

Analysis by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others

Retail pharmacies represent the leading segment, with a market share of 48%. Retail pharmacies serve as the primary distribution channel for migraine drugs due to their widespread geographic presence, accessibility, and ability to provide over-the-counter and prescription medications to a broad patient population. The convenience of neighborhood retail pharmacy locations enables patients to obtain migraine treatments promptly, which is crucial given the episodic and unpredictable nature of migraine attacks. Retail pharmacies also play a vital role in patient education, medication counseling, and adherence support, contributing to improved treatment outcomes. The extensive network of retail pharmacy outlets across urban, suburban, and rural areas ensures broad distribution coverage, enabling patients in diverse geographic settings to access essential migraine medications without significant delays. Furthermore, the growing integration of digital prescription services and online ordering platforms within retail pharmacy operations is enhancing patient access to migraine drugs. The expansion of pharmacy chains into underserved communities and the increasing adoption of home delivery services are further broadening the distribution reach of migraine treatments and improving overall convenience for patients.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 30% of the share, enjoys the leading position in the market. The region benefits from a highly developed healthcare infrastructure, widespread insurance coverage, and strong adoption of novel migraine therapies, including CGRP-targeted monoclonal antibodies and oral gepants. The United States, as the largest contributor within North America, has a substantial migraine patient population, driving consistent demand for both acute and preventive treatment options. The presence of leading pharmaceutical companies and a robust clinical trial ecosystem further supports the continuous introduction of innovative migraine drugs in the region. The well-established regulatory framework and streamlined drug approval processes facilitate the timely availability of newly developed therapies, ensuring that patients benefit from the latest advancements in migraine care. Moreover, favorable regulatory pathways and government initiatives aimed at improving neurological disease management are reinforcing North America's dominant position in the global migraine drugs market. The growing emphasis on patient-centric healthcare delivery models and the rising adoption of multidisciplinary headache treatment centers across the region are also contributing to improved treatment outcomes and sustained market leadership.

Key Regional Takeaways:

United States Migraine Drugs Market Analysis

The United States represents the largest national market for migraine drugs globally, driven by the high prevalence of migraine disorders and the well-established healthcare system that supports broad access to advanced treatment options. The strong adoption of novel CGRP-targeted therapies, including both injectable monoclonal antibodies and oral gepants, is significantly contributing to market expansion. The availability of comprehensive insurance coverage for prescription migraine medications, including preventive therapies, is enabling patients to access innovative treatments without prohibitive out-of-pocket costs. Additionally, the robust presence of major pharmaceutical companies and research institutions is fostering a dynamic pipeline of migraine drug candidates. The country also benefits from a well-structured regulatory framework that facilitates the timely approval and commercialization of novel migraine therapies, ensuring patients have access to the latest treatment advancements. The increasing utilization of telemedicine platforms for migraine consultations and prescription management is further improving patient access and treatment adherence. Furthermore, growing awareness campaigns and advocacy efforts aimed at reducing the stigma associated with migraine and promoting early diagnosis are driving improved treatment-seeking behavior across the country. The rising emphasis on multidisciplinary headache treatment approaches within specialized neurology centers is also enhancing patient outcomes and supporting sustained market growth.

Europe Migraine Drugs Market Analysis

The European migraine drugs market is driven by the high prevalence of migraine disorders across the region and the increasing adoption of advanced treatment modalities. The well-established public healthcare systems in major European economies, including Germany, France, the United Kingdom, Italy, and Spain, provide broad access to both conventional and novel migraine therapies. The growing emphasis on evidence-based treatment guidelines and the integration of CGRP-targeted therapies into national formularies are supporting market expansion. The region also benefits from a strong network of academic medical centers and research institutions that are actively advancing the understanding of migraine pathophysiology and developing innovative therapeutic approaches. Additionally, the increasing investment in neurological research and clinical trials across European healthcare institutions is accelerating the development of next-generation migraine treatments. The growing awareness about migraine as a disabling neurological condition is encouraging earlier diagnosis and appropriate treatment. The expanding collaboration between public health agencies and patient advocacy organizations is further driving education initiatives aimed at improving migraine management across diverse patient populations.

Asia-Pacific Migraine Drugs Market Analysis

The Asia-Pacific migraine drugs market is experiencing significant growth driven by the rising prevalence of migraine disorders across the region and improving healthcare infrastructure. The large population base in countries such as China, India, and Japan, combined with increasing urbanization and lifestyle-related stress factors, is contributing to the growing burden of migraine. The region faces a substantial disease burden due to rapidly changing dietary patterns, increasing work-related stress, and limited access to specialized neurological care in many rural and semi-urban areas. The expanding availability of advanced treatment options and the growing penetration of pharmaceutical companies into emerging Asian markets are further supporting market development. Additionally, government initiatives aimed at improving neurological disease awareness and healthcare access are encouraging treatment-seeking behavior among migraine patients.

Latin America Migraine Drugs Market Analysis

The Latin American migraine drugs market is driven by the increasing prevalence of migraine disorders and improving access to pharmaceutical treatments across the region. The growing burden of migraine in countries such as Brazil and Mexico, combined with expanding healthcare coverage and rising awareness about neurological conditions, is supporting market growth. The region is witnessing a gradual shift toward the adoption of newer therapeutic classes as healthcare systems modernize and physician awareness of advanced treatment options improves. The ongoing development of healthcare infrastructure and the increasing availability of both generic and branded migraine medications are further broadening treatment access for patients in the region.

Middle East and Africa Migraine Drugs Market Analysis

The Middle East and Africa migraine drugs market is supported by the growing awareness of migraine as a neurological disorder and the expanding healthcare infrastructure across the region. The increasing urbanization, rising disposable incomes, and the growing prevalence of lifestyle-related health conditions are contributing to the rising demand for migraine treatments. The region is also benefiting from the expanding network of specialized neurology clinics and the increasing availability of trained healthcare professionals who can accurately diagnose and manage migraine conditions. The ongoing investment in healthcare facilities and the expanding presence of pharmaceutical companies in the region are improving access to both acute and preventive migraine therapies.

Competitive Landscape:

The competitive landscape of the migraine drugs market is characterized by intense rivalry among established pharmaceutical companies that are actively investing in research and development to expand their product portfolios. Key market players are focusing on the development and commercialization of novel CGRP-targeted therapies, combination drugs, and innovative delivery systems to address unmet treatment needs. Strategic initiatives, including mergers and acquisitions, licensing agreements, and collaborative research partnerships, are being pursued to strengthen market positions and accelerate pipeline development. Companies are also emphasizing the expansion of geographic reach through regulatory filings in emerging markets and the establishment of distribution networks. The increasing competition among branded therapies, coupled with the growing availability of generic formulations for older drug classes such as triptans, is influencing pricing strategies and market dynamics. Furthermore, the focus on achieving regulatory approvals for pediatric and expanded indications is enabling companies to broaden their addressable patient populations.

The report provides a comprehensive analysis of the competitive landscape in the migraine drugs market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan Plc (Abbvie Inc.)
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Limited

Key Questions Answered in This Report

  • 1.How big is the migraine drugs market?
  • 2.What is the future outlook of migraine drugs market?
  • 3.What are the key factors driving the migraine drugs market?
  • 4.Which region accounts for the largest migraine drugs market share?
  • 5.Which are the leading companies in the global migraine drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2025
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2025
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players